| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Krämer, A.
|
|
|
34 |
3 |
p. 228-246
|
article
|
| 2 |
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
|
Scalera, S.
|
|
|
34 |
3 |
p. 275-288
|
article
|
| 3 |
Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”
|
Van Baelen, K.
|
|
|
34 |
3 |
p. 326
|
article
|
| 4 |
Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Zucca, E.
|
|
|
34 |
3 |
p. 325
|
article
|
| 5 |
Corrigendum to “MO10-6 miR-4647 an early biomarker of outcome in chronic myeloid leukaemia patients”
|
Guru, S.A.
|
|
|
34 |
3 |
p. 323
|
article
|
| 6 |
Corrigendum to “Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation”
|
Takamatsu, H.
|
|
|
34 |
3 |
p. 322
|
article
|
| 7 |
Corrigendum to “23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali”
|
Brahmantya, I.B.Y.
|
|
|
34 |
3 |
p. 321
|
article
|
| 8 |
Corrigendum to “12P The efficacy of EGFR tyrosine kinase inhibitors and its clinical prognostic factors in lung adenocarcinoma patients harboring different types of EGFR mutations: Real-world data”
|
Vicente, R.
|
|
|
34 |
3 |
p. 324
|
article
|
| 9 |
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|
Psyrri, A.
|
|
|
34 |
3 |
p. 262-274
|
article
|
| 10 |
Editorial Board
|
|
|
|
34 |
3 |
p. iii
|
article
|
| 11 |
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up ☆
|
Balar, A.V.
|
|
|
34 |
3 |
p. 289-299
|
article
|
| 12 |
ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease
|
Bossi, P.
|
|
|
34 |
3 |
p. 247-250
|
article
|
| 13 |
Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation
|
Kwapisz, D.
|
|
|
34 |
3 |
p. 315-318
|
article
|
| 14 |
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
|
Kuzbari, Z.
|
|
|
34 |
3 |
p. 215-227
|
article
|
| 15 |
Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy
|
White, K.
|
|
|
34 |
3 |
p. 300-314
|
article
|
| 16 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.
|
|
|
34 |
3 |
p. 251-261
|
article
|
| 17 |
Table of Contents
|
|
|
|
34 |
3 |
p. i-ii
|
article
|
| 18 |
“Timing is Everything”: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma
|
Rosenberg, A.J.
|
|
|
34 |
3 |
p. 213-214
|
article
|
| 19 |
VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
|
Rha, S.Y.
|
|
|
34 |
3 |
p. 319-320
|
article
|
Journal description